How HCG Affects Testosterone

HCG shares structural homology with LH and binds the LH/CG receptor on Leydig cells with equivalent or higher affinity. This directly stimulates the steroidogenic enzyme cascade (StAR protein, CYP11A1, CYP17A1, HSD17B3), converting cholesterol to testosterone within the testes. The critical distinction is between intratesticular testosterone (ITT) and serum testosterone. ITT is approximately 50-100 times higher than serum testosterone and is essential for normal spermatogenesis. During exogenous testosterone administration, gonadotropins (LH and FSH) are suppressed, ITT falls by more than 95%, and spermatogenesis is impaired. HCG maintains ITT by bypassing the suppressed pituitary and directly stimulating Leydig cells. In a landmark dose-finding study by Coviello et al. (2005), 250 IU HCG every other day maintained ITT within 7% of baseline values, while 500 IU raised ITT 26% above baseline.

At 250 IU every other day: ITT maintained near baseline; serum testosterone rises modestly (10-20% above the testosterone-only level, because the testicular contribution adds to circulating levels). At 500 IU every other day: ITT rises 26% above baseline; serum testosterone rises more noticeably. The serum testosterone effect is dose-dependent but is not the primary therapeutic target. In men already on TRT, the net serum testosterone change from adding HCG depends heavily on the pre-existing exogenous testosterone dose.

Serum testosterone is an imperfect proxy for ITT during HCG use: normal serum testosterone does not guarantee adequate ITT for spermatogenesis. The most relevant monitoring tools are semen analysis (every 3-6 months for men actively trying to conceive) and LH/FSH as indirect markers of endogenous gonadotropin suppression. If fertility is not the immediate goal, serum testosterone monitoring every 6-12 months on a stable TRT plus HCG protocol is appropriate. Do not increase HCG dose to chase higher serum testosterone numbers.

Use the lowest HCG dose that achieves the clinical goal. For fertility preservation on TRT, 250 IU every other day is the evidence-supported starting dose. Higher doses increase estradiol disproportionately without proportionally greater ITT benefit. If pregnancy is not being actively pursued and fertility preservation is the goal, 250 IU every other day or 500 IU twice weekly are standard options. For men discontinuing TRT to restore natural testosterone production, HCG 500-1,500 IU three times weekly for 4-6 weeks is commonly used as a bridge before adding SERMs.